按美国人口普查分区分层的铜绿假单胞菌对头孢他啶-阿维巴坦、头孢洛扎-他唑巴坦、哌拉西林-他唑巴坦和美罗培南的药敏性：来自 2017 年 INFORM 项目的结果。
Antimicrobial Susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM Program.
机构信息
JMI Laboratories, North Liberty, Iowa, USA
JMI Laboratories, North Liberty, Iowa, USA.
出版信息
Antimicrob Agents Chemother. 2018 Nov 26;62(12). doi: 10.1128/AAC.01587-18. Print 2018 Dec.
Abstract
isolates ( = 1,909) were collected from 70 U.S. medical centers, and their susceptibilities were tested using the broth microdilution method. Ceftazidime-avibactam (MIC/MIC, 2/8 mg/liter) and ceftolozane-tazobactam (MIC/MIC, 0.5/2 mg/liter) were the most active (i.e., had the highest susceptibility rates) compounds after colistin, with national susceptibility rates of 96.9% and 97.5%, respectively. Overall, piperacillin-tazobactam (MIC/MIC, 4/128 mg/liter) and meropenem (MIC/MIC, 0.5/16 mg/liter) were active against 77.5% and 76.0% of the isolates, respectively. Susceptibility variations across census divisions were documented for many antimicrobials.
摘要
从 70 家美国医疗中心采集了 1909 株分离株，并采用肉汤微量稀释法检测它们的药敏性。头孢他啶-阿维巴坦（MIC/MIC，2/8 毫克/升）和头孢洛扎-他唑巴坦（MIC/MIC，0.5/2 毫克/升）在粘菌素之后是最有效的（即具有最高的敏感性率）化合物，其全国敏感性率分别为 96.9%和 97.5%。总体而言，哌拉西林-他唑巴坦（MIC/MIC，4/128 毫克/升）和美罗培南（MIC/MIC，0.5/16 毫克/升）对分别 77.5%和 76.0%的分离株具有活性。许多抗菌药物在普查区之间都有记录到药敏性的变化。
相似文献
1
Antimicrobial Susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM Program.按美国人口普查分区分层的铜绿假单胞菌对头孢他啶-阿维巴坦、头孢洛扎-他唑巴坦、哌拉西林-他唑巴坦和美罗培南的药敏性：来自 2017 年 INFORM 项目的结果。
Antimicrob Agents Chemother. 2018 Nov 26;62(12). doi: 10.1128/AAC.01587-18. Print 2018 Dec.
2
Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of and .2017 年中国抗菌药物监测网（CHINET）对临床分离的 和 的头孢他啶-阿维巴坦和头孢唑南-他唑巴坦活性研究结果。
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02431-18. Print 2019 Apr.
3
Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.美国最佳耐药性监测计划国际网络四年（2012年至2015年）期间铜绿假单胞菌的抗菌药敏结果
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02252-16. Print 2017 Mar.
4
Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.耐哌拉西林/他唑巴坦铜绿假单胞菌对头孢他啶/阿维巴坦、头孢洛扎/他唑巴坦和碳青霉烯类药物耐药性的系统进化分析。
Int J Antimicrob Agents. 2019 Jun;53(6):774-780. doi: 10.1016/j.ijantimicag.2019.02.022. Epub 2019 Mar 2.
5
Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.2011年至2015年在美国医疗中心住院治疗肺炎的患者中分离出的革兰氏阴性菌对头孢他啶-阿维巴坦的抗菌活性
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02083-16. Print 2017 Apr.
6
In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: A two-centre study.体外研究头孢洛扎他唑巴坦和头孢他啶-阿维巴坦对耐美罗培南铜绿假单胞菌临床分离株的活性：一项多中心研究。
J Glob Antimicrob Resist. 2020 Mar;20:334-338. doi: 10.1016/j.jgar.2019.09.016. Epub 2019 Sep 27.
7
Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested Against and Isolates from United States Medical Centers in 2016-2018.2016-2018 年美国医疗中心分离的 和 菌株的抗菌活性：头孢他啶-阿维巴坦、头孢洛扎-他唑巴坦及对照药物的检测
Microb Drug Resist. 2021 Mar;27(3):342-349. doi: 10.1089/mdr.2020.0217. Epub 2020 Aug 7.
8
Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.2013 年至 2015 年期间，美国住院患者呼吸道标本中分离的铜绿假单胞菌和肠杆菌科细菌对头孢他洛滨-他唑巴坦的活性。
Antimicrob Agents Chemother. 2018 Feb 23;62(3). doi: 10.1128/AAC.02125-17. Print 2018 Mar.
9
Ceftazidime-avibactam and ceftolozane-tazobactam susceptibility of multidrug resistant Pseudomonas aeruginosa strains in Hungary.匈牙利耐多药铜绿假单胞菌中头孢他啶-阿维巴坦和头孢洛扎-他唑巴坦的药敏情况。
Acta Microbiol Immunol Hung. 2020 Mar 26;67(1):61-65. doi: 10.1556/030.2020.01152.
10
Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.头孢他啶/阿维巴坦、头孢洛扎/他唑巴坦、亚胺培南/雷巴坦、美罗培南/沃巴坦和对照药物对皮肤软组织感染患者分离的铜绿假单胞菌的抗菌活性。
Int J Infect Dis. 2021 Dec;113:279-281. doi: 10.1016/j.ijid.2021.10.022. Epub 2021 Oct 17.
引用本文的文献
1
Frequency, Antimicrobial Susceptibility, and Molecular Characterization of Carbapenem-Resistant Enterobacterales Stratified by United States Census Divisions: Results From the INFORM Program (2018-2022).按美国人口普查分区划分的耐碳青霉烯类肠杆菌科细菌的频率、药敏性及分子特征：INFORM项目（2018 - 2022年）的结果
Open Forum Infect Dis. 2025 Apr 11;12(4):ofaf005. doi: 10.1093/ofid/ofaf005. eCollection 2025 Apr.
2
Ceftazidime-avibactam use selects multidrug-resistance and prevents designing collateral sensitivity-based therapies against Pseudomonas aeruginosa.使用头孢他啶-阿维巴坦会选择多重耐药性，并阻碍设计针对铜绿假单胞菌的基于协同敏感性的疗法。
Nat Commun. 2025 Apr 9;16(1):3323. doi: 10.1038/s41467-025-58597-6.
3
Temperate phage-antibiotic synergy is widespread-extending to -but varies by phage, host strain, and antibiotic pairing.温和噬菌体与抗生素的协同作用广泛存在，适用于多种情况，但会因噬菌体、宿主菌株和抗生素组合的不同而有所差异。
mBio. 2025 Feb 5;16(2):e0255924. doi: 10.1128/mbio.02559-24. Epub 2024 Dec 20.
4
Prevalence of colistin resistance in clinical isolates of : a systematic review and meta-analysis.临床分离株中黏菌素耐药性的流行情况：一项系统评价和荟萃分析。
Front Microbiol. 2024 Oct 9;15:1477836. doi: 10.3389/fmicb.2024.1477836. eCollection 2024.
5
Bayesian estimation of the prevalence of antimicrobial resistance: a mathematical modelling study.贝叶斯估计抗菌药物耐药率：一项数学建模研究。
J Antimicrob Chemother. 2024 Sep 3;79(9):2317-2326. doi: 10.1093/jac/dkae230.
6
Piperacillin/tazobactam treatment in children: evidence of subtherapeutic concentrations.儿童使用哌拉西林/他唑巴坦治疗：亚治疗浓度的证据。
Front Pharmacol. 2024 Jul 4;15:1254005. doi: 10.3389/fphar.2024.1254005. eCollection 2024.
7
Ethynyl-substituted benzosiloxaboroles: the role of C(π)⋯B interactions in their crystal packing and use in Cu(i)-catalyzed 1,3-dipolar cycloaddition.乙炔基取代的苯并硅硼杂环戊二烯：C(π)⋯B相互作用在其晶体堆积中的作用及其在铜（I）催化的1,3-偶极环加成反应中的应用
RSC Adv. 2024 May 17;14(23):16069-16082. doi: 10.1039/d4ra02137a. eCollection 2024 May 15.
8
Antimicrobial susceptibility pattern of aerobic bacteria responsible for post-surgical wound infection of the patients admitted into Khulna Medical College Hospital, Bangladesh.孟加拉国库尔纳医学院医院收治患者术后伤口感染的需氧菌抗菌药敏模式。
Access Microbiol. 2024 Feb 13;6(2):000401. doi: 10.1099/acmi.0.000401. eCollection 2024.
9
Extensively drug-resistant : clinical features and treatment with ceftazidime/avibactam and ceftolozane/tazobactam in a tertiary care university hospital center in Portugal - A cross-sectional and retrospective observational study.广泛耐药：葡萄牙一家三级医疗大学医院中心的临床特征及使用头孢他啶/阿维巴坦和头孢洛扎/他唑巴坦治疗——一项横断面回顾性观察研究
Front Microbiol. 2024 Feb 13;15:1347521. doi: 10.3389/fmicb.2024.1347521. eCollection 2024.
10
Biofilm formation: mechanistic insights and therapeutic targets.生物膜形成：机制见解与治疗靶点。
Mol Biomed. 2023 Dec 15;4(1):49. doi: 10.1186/s43556-023-00164-w.
本文引用的文献
1
Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.2013 年至 2015 年期间，美国住院患者呼吸道标本中分离的铜绿假单胞菌和肠杆菌科细菌对头孢他洛滨-他唑巴坦的活性。
Antimicrob Agents Chemother. 2018 Feb 23;62(3). doi: 10.1128/AAC.02125-17. Print 2018 Mar.
2
Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.美国最佳耐药性监测计划国际网络四年（2012年至2015年）期间铜绿假单胞菌的抗菌药敏结果
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02252-16. Print 2017 Mar.
3
Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014.与医疗保健相关感染有关的耐抗菌性病原体：2011 - 2014年向疾病控制与预防中心国家医疗保健安全网络报告的数据摘要
Infect Control Hosp Epidemiol. 2016 Nov;37(11):1288-1301. doi: 10.1017/ice.2016.174. Epub 2016 Aug 30.
4
Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.头孢他啶/阿维巴坦和头孢洛扎/他唑巴坦：第二代β-内酰胺/β-内酰胺酶抑制剂组合
Clin Infect Dis. 2016 Jul 15;63(2):234-41. doi: 10.1093/cid/ciw243. Epub 2016 Apr 20.
5
Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.头孢他啶-阿维巴坦和头孢洛扎-他唑巴坦对耐美罗培南铜绿假单胞菌分离株的体外活性评估。
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3227-31. doi: 10.1128/AAC.02969-15. Print 2016 May.
6
Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins.β-内酰胺酶AmpC突变增加铜绿假单胞菌分离株对抗假单胞菌头孢菌素的耐药性。
Antimicrob Agents Chemother. 2015 Oct;59(10):6248-55. doi: 10.1128/AAC.00825-15. Epub 2015 Jul 27.
7
Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.头孢洛扎他唑巴坦和头孢他啶/阿维巴坦：两种新型β-内酰胺/β-内酰胺酶抑制剂复方制剂，用于治疗耐药革兰氏阴性菌感染。
Int J Antimicrob Agents. 2015 Sep;46(3):266-71. doi: 10.1016/j.ijantimicag.2015.05.003. Epub 2015 Jun 14.
8
An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance.铜绿假单胞菌医院获得性肺炎的国际多中心回顾性研究：多重耐药性的影响
Crit Care. 2015 May 6;19(1):219. doi: 10.1186/s13054-015-0926-5.
Zotero 插件